N. prodotti: 0
Totale ordine: € 0,00
Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752
Online ISSN 1827-1618
Mcafee A. T., Rodríguez L. A. G., Goettsch W. G., González-Pérez A., Johansson S., Ming E. E., Wallander M.-A., Herings R. M. C.
1 Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
2 Centro Español de Investigación Farmacoepidemiológica (CEIFE), Madrid, Spain
3 PHARMO Institute, Utrecht, The Netherlands
4 Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
5 Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
6 Public Health and Caring Science Uppsala University, Uppsala, Sweden
7 Department of Health Policy & Management, Erasmus Medical Centre, Rotterdam,
Aim. This study was undertaken to increase understanding of the utilization of a newly introduced statin through evaluation of characteristics of ‘real-life’ patients in a pharmacoepidemiology program in the USA, the Netherlands, the UK and Canada.
Methods. This was an observational analysis of prospectively collected data from primary care patients classified as new users of rosuvastatin or any other statin. New users (naïve or switched initiators) of rosuvastatin were compared with initiators of other statins, as identified from automated healthcare databases in the first 1 to 2 years of rosuvastatin availability. Demographics, statin doses, previous statin use and other lipid-lowering therapies, and relevant comorbidities were recorded. The main outcome measure was proportion of naïve and non-naïve statin users in patients prescribed rosuvastatin or ‘other statins’.
Results. Among 346 547 new statin users identified in the cohorts, 46 838 (13.5%) were new users of rosuvastatin and most (84.1%) were statin-naïve. Patients receiving rosuvastatin were more likely to have been previously treated with another statin or non-statin lipid-lowering therapy and tended to be younger, compared with first users of other statins.
Conclusion. These findings suggest that rosuvastatin is preferentially prescribed to patients who have not responded satisfactorily to established treatment.